Spago Nanomedical AB (publ) (FRA:7UX)

Market Cap	7.43M +15.4%
Revenue (ttm)	445.57K -27.5%
Net Income	-2.45M
EPS	-0.01
Shares Out	n/a
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	n/a
Average Volume	n/a
Open	0.0056
Previous Close	0.0090
Day's Range	0.0056 - 0.0092
52-Week Range	0.0042 - 0.0292
Beta	n/a
RSI	51.19
Earnings Date	May 6, 2026

About Spago Nanomedical AB

Spago Nanomedical AB (publ), a clinical phase nanomedicine company, engages in the development of nanomedicines for cancer diagnostics and treatment primarily in Sweden. Its products include SpagoPix (SN132D), an MRI contrast agent, which is under Phase I development stage for the treatment of breast cancer, and under Phase II development stage for the treatment liver and pancreas cancer, as well as offers Tumorad (SN201), a radionuclide therapy for treatment of advanced and metastatic cancer, under preclinical development stage. The company wa...

• Industry: Biological Products, Except Diagnostic Substances
• Founded: 1999
• Employees: 7
• Stock Exchange: Frankfurt Stock Exchange
• Ticker Symbol: 7UX

Financial Performance

In 2025, Spago Nanomedical AB's revenue was 4.82 million, a decrease of -27.53% compared to the previous year's 6.65 million. Losses were -26.55 million, -18.32% less than in 2024.

Financial numbers in SEK